Block Copolymer Comprising at least one Polyester Block and at least one Poly(ethylene glycol) Block

Abstract

The present invention provides a block copolymer for a coating on an implantable device for controlling release of drug and methods of making and using the same.

1 . An implantable device, comprising a block copolymer, the block copolymer comprising at least one polyester block and at least one poly(ethylene glycol) (PEG) block,
 wherein:   the PEG block has a weight average molecular weight (M w ) from about 1,000 Daltons to about 30,000 Daltons,   the block copolymer is biosoluble, and   upon exposure to a physiological environment, 80% mass of the block copolymer will dissolve in a period of about 1 day to about 90 days.   
     
     
         2 . The implantable device of  claim 1 , wherein the polyester block comprises glycolide. 
     
     
         3 . The implantable device of  claim 1 , wherein the polyester block comprises lactide. 
     
     
         4 . The implantable device of  claim 1 , wherein the lactide comprises D,L-lactide, L-lactide, D-lactide, meso-lactide or combinations thereof 
     
     
         5 . The implantable device of  claim 3 , wherein the block copolymer forms a coating on the implantable device, the coating comprising a semi-crystalline morphology, and wherein the lactide in the polyester block has a molar concentration of at least 60%. 
     
     
         6 . The implantable device of  claim 5 , wherein the lactide in the polyester block has a molar concentration of at least 80%. 
     
     
         7 . The implantable device of  claim 2 , wherein the glycolide in the polyester block has a molar concentration of between about 10% and about 75%. 
     
     
         8 . The implantable device of  claim 1 , wherein the block copolymer comprises biodegradable side blocks. 
     
     
         9 . The implantable device of  claim 8 , wherein the side blocks are selected from the group consisting of polyanhydrides, poly(ester amides), polythioesters, and combinations thereof 
     
     
         10 . The implantable device of  claim 1 , wherein the polyester block comprises units from caprolactone. 
     
     
         11 . The implantable device of  claim 1 , wherein the block copolymer is an alternating A-B block copolymer where A is a poly(lactide-co-glycolide) (PLGA) block and B is the PEG block. 
     
     
         12 . The implantable device of  claim 1 , wherein the block copolymer is selected from the group consisting of poly(lactide-co-glycolide-co-caprolactone)-block-PEG-poly(lactide-co-glycolide-co-caprolactone), poly(trimethylene carbonate-co-glycolide)-block-PEG-block-poly (trimethylene carbonate-co-glycolide), polylactide-block-PEG-polyactide, poly(trimethylene carbonate-co-glycolide)-block-PEG-poly(trimethylene carbonate-co-glycolide), and combinations thereof 
     
     
         13 . The implantable device of  claim 1 , wherein the block copolymer has a M w  of about 60,000 Daltons or higher. 
     
     
         14 . The implantable device of  claim 1 , wherein the block copolymer has a M w  of about 100,000 Daltons or higher. 
     
     
         15 . The implantable device of  claim 1 , wherein the block copolymer forms a coating on the implantable device. 
     
     
         16 . The implantable device of  claim 1 , wherein the block copolymer forms at least a portion of the body structure of the implantable device. 
     
     
         17 . The implantable device of  claim 15 , wherein the coating further comprises a bioactive agent. 
     
     
         18 . The implantable device of  claim 17 , wherein the bioactive agent is selected from paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), biolimus, tacrolimus, dexamethasone, dexamethasone acetate, corticosteroids, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), zotarolimus, Biolimus A9 (Biosensors International, Singapore), AP23572 (Ariad Pharmaceuticals), γ-hiridun, clobetasol, pimecrolimus, imatinib mesylate, midostaurin, cRGD, feno fibrate, prodrugs thereof, co-drugs thereof, and combinations thereof 
     
     
         19 . The implantable device of  claim 1 , which is a stent. 
     
     
         20 . The implantable device of  claim 1 , which is a bioabsorbable stent.